OncoMatch/Leukemia — Acute Myeloid (AML)/TP53
Leukemia — Acute Myeloid (AML)TP53 Clinical Trials
TP53 mutations occur in 5–10% of AML and are strongly associated with complex karyotype, therapy-related AML, and very poor prognosis with standard therapies. No agent is yet specifically approved for TP53-mutant AML, though eprenetapopt (APR-246) and decitabine/cedazuridine combinations have been studied. Trials evaluate novel p53-reactivating agents, hypomethylating regimens, and allogeneic transplant strategies for this high-risk population.
Top recruiting TP53 Leukemia — Acute Myeloid (AML) trials
Ranked by phase and US site count.
See all trials matched to your profile →Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Masonic Cancer Center, University of Minnesota
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
St. Petersburg State Pavlov Medical University
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
St. Petersburg State Pavlov Medical University
Oral-ATO for TP53-mutated Myeloid Malignancies
The University of Hong Kong